Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXGN NASDAQ:BBNX NASDAQ:ESTA NASDAQ:NVCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$42.80+1.0%$38.34$9.22▼$45.83$2.28B1.12769,540 shs800,160 shsBBNXBeta Bionics$13.89$10.93$8.80▼$32.71$618.97M3.4738,198 shs1.01 million shsESTAEstablishment Labs$74.31-2.9%$66.49$33.35▼$83.31$2.19B1.11418,884 shs350,097 shsNVCRNovoCure$17.16-4.6%$14.40$9.82▼$19.25$1.99B0.931.48 million shs2.14 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen+0.97%+8.41%-1.56%+49.91%+292.66%BBNXBeta Bionics0.00%+14.60%+31.41%+30.91%-28.59%ESTAEstablishment Labs-2.85%+5.12%-0.43%+5.58%+99.87%NVCRNovoCure-4.61%+0.70%+4.00%+31.60%+2.63%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$42.80+1.0%$38.34$9.22▼$45.83$2.28B1.12769,540 shs800,160 shsBBNXBeta Bionics$13.89$10.93$8.80▼$32.71$618.97M3.4738,198 shs1.01 million shsESTAEstablishment Labs$74.31-2.9%$66.49$33.35▼$83.31$2.19B1.11418,884 shs350,097 shsNVCRNovoCure$17.16-4.6%$14.40$9.82▼$19.25$1.99B0.931.48 million shs2.14 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen+0.97%+8.41%-1.56%+49.91%+292.66%BBNXBeta Bionics0.00%+14.60%+31.41%+30.91%-28.59%ESTAEstablishment Labs-2.85%+5.12%-0.43%+5.58%+99.87%NVCRNovoCure-4.61%+0.70%+4.00%+31.60%+2.63%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXGNAxoGen 2.73Moderate Buy$46.508.64% UpsideBBNXBeta Bionics 2.64Moderate Buy$19.7041.83% UpsideESTAEstablishment Labs 2.63Moderate Buy$87.1417.27% UpsideNVCRNovoCure 2.38Hold$27.2959.01% UpsideCurrent Analyst Ratings BreakdownLatest BBNX, AXGN, ESTA, and NVCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026NVCRNovoCure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/29/2026AXGNAxoGen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/29/2026AXGNAxoGen Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/27/2026BBNXBeta Bionics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$19.00 ➝ $17.005/18/2026BBNXBeta Bionics Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$23.00 ➝ $11.005/7/2026ESTAEstablishment Labs BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$88.00 ➝ $90.005/6/2026ESTAEstablishment Labs CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral5/4/2026NVCRNovoCure Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$13.50 ➝ $17.005/1/2026NVCRNovoCure EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform4/29/2026AXGNAxoGen Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$48.004/29/2026AXGNAxoGen Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$45.00 ➝ $50.00(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXGNAxoGen$225.21M10.11N/AN/A$2.79 per share15.34BBNXBeta Bionics$100.25M6.17N/AN/A$6.53 per share2.13ESTAEstablishment Labs$211.08M10.36N/AN/A$0.81 per share91.74NVCRNovoCure$655.35M3.03N/AN/A$3.04 per share5.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXGNAxoGen-$15.70M-$0.64N/A158.52N/A-13.21%-9.63%-6.26%8/4/2026 (Estimated)BBNXBeta Bionics-$73.20M-$1.51N/AN/AN/A-60.27%-23.00%-20.55%N/AESTAEstablishment Labs-$51.06M-$1.49N/A530.79N/A-19.05%-218.77%-12.31%8/6/2026 (Estimated)NVCRNovoCure-$136.23M-$1.53N/AN/AN/A-25.66%-50.82%-16.48%7/23/2026 (Estimated)Latest BBNX, AXGN, ESTA, and NVCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026ESTAEstablishment Labs-$0.3550-$0.45-$0.0951-$0.45$57.40 million$59.88 million4/30/2026Q1 2026NVCRNovoCure-$0.5122-$0.62-$0.1078-$0.62$167.77 million$174.06 million4/28/2026Q1 2026AXGNAxoGen$0.12$0.07-$0.05-$0.38$57.85 million$61.46 million4/21/2026Q1 2026BBNXBeta Bionics-$0.53-$0.49+$0.04-$0.49N/A$27.63 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAXGNAxoGenN/AN/AN/AN/AN/ABBNXBeta BionicsN/AN/AN/AN/AN/AESTAEstablishment LabsN/AN/AN/AN/AN/ANVCRNovoCureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXGNAxoGen0.087.105.33BBNXBeta BionicsN/A10.699.67ESTAEstablishment Labs16.822.961.91NVCRNovoCure0.712.902.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXGNAxoGen80.29%BBNXBeta BionicsN/AESTAEstablishment Labs72.91%NVCRNovoCure84.61%Insider OwnershipCompanyInsider OwnershipAXGNAxoGen2.44%BBNXBeta Bionics5.30%ESTAEstablishment Labs9.99%NVCRNovoCure5.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXGNAxoGen45053.18 million51.88 millionOptionableBBNXBeta Bionics29444.56 million42.20 millionN/AESTAEstablishment Labs1,00429.43 million26.49 millionOptionableNVCRNovoCure1,605115.82 million109.43 millionOptionableBBNX, AXGN, ESTA, and NVCR HeadlinesRecent News About These CompaniesNovocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company UpdateJune 6 at 9:05 AM | finanznachrichten.deInsider Selling: NovoCure (NASDAQ:NVCR) CEO Sells 34,273 Shares of StockJune 6 at 7:43 AM | insidertrades.comNovoCure Shareholders Approve Directors, Auditor and Incentive PlanJune 5 at 5:50 PM | tipranks.comNovoCure (NASDAQ:NVCR) Stock Price Up 8.2% - Here's What HappenedJune 4 at 12:41 PM | marketbeat.comW Anthony Vernon Sells 2,945 Shares of NovoCure (NASDAQ:NVCR) StockJune 4 at 8:34 AM | insidertrades.comContrasting NovoCure (NASDAQ:NVCR) and HUTCHMED (NASDAQ:HCM)May 30, 2026 | americanbankingnews.comNovoCure Limited (NASDAQ:NVCR) Given Average Rating of "Hold" by BrokeragesMay 20, 2026 | marketbeat.comVanguard Group Inc. Has $141.69 Million Position in NovoCure Limited $NVCRMay 12, 2026 | marketbeat.comStocks with rising relative price strength: NovocureMay 4, 2026 | msn.comInternational Markets and NovoCure (NVCR): A Deep Dive for InvestorsMay 4, 2026 | zacks.comNovoCure Limited (NASDAQ:NVCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?May 2, 2026 | finance.yahoo.comNovoCure: Pancreatic Launch Looks Promising, But I'm Not A Believer YetMay 1, 2026 | seekingalpha.comNovoCure: Q1 Earnings SnapshotMay 1, 2026 | chron.comNovocure jumps after raising FY26 sales outlook, Q1 revenue beatMay 1, 2026 | seekingalpha.comTwo medical stocks skyrocket after demolishing views — and one is about to break outMay 1, 2026 | msn.comNovoCure (NVCR) Q1 2026 Earnings TranscriptMay 1, 2026 | finance.yahoo.comWhy NovoCure Limited’s (NVCR) Stock Is Up 19.53%May 1, 2026 | aaii.comANovoCure Limited (NVCR) Q1 2026 Earnings Call TranscriptApril 30, 2026 | seekingalpha.comNovoCure (NVCR) Reports Q1 Loss, Beats Revenue EstimatesApril 30, 2026 | zacks.comNovoCure Limited 2026 Q1 - Results - Earnings Call PresentationApril 30, 2026 | seekingalpha.comH.C. Wainwright Keeps Their Buy Rating on NovoCure (NVCR)April 21, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesCAVA Group’s Stock Looks Delicious After Strong EarningsBy Chris Markoch | May 22, 2026McDonald's Is the Cheapest It’s Been in Years—Does That Make It a Buy?By Sam Quirke | May 15, 2026Shake Shack Stock Gets Shaken After Earnings MissBy Jennifer Ryan Woods | May 12, 20263 Ways to Play the Data Center Land GrabBy Nathan Reiff | May 31, 2026A Real Biggie Deal: Wendy's Serves Up a Juicy Buyout ArbitrageBy Jeffrey Neal Johnson | May 13, 2026BBNX, AXGN, ESTA, and NVCR Company DescriptionsAxoGen NASDAQ:AXGN$42.80 +0.41 (+0.97%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$42.47 -0.33 (-0.76%) As of 06/5/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.Beta Bionics NASDAQ:BBNX$13.89 0.00 (0.00%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$13.99 +0.10 (+0.72%) As of 06/5/2026 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.Establishment Labs NASDAQ:ESTA$74.31 -2.18 (-2.85%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$74.33 +0.02 (+0.03%) As of 06/5/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.NovoCure NASDAQ:NVCR$17.16 -0.83 (-4.61%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$17.16 0.00 (0.00%) As of 06/5/2026 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
